BARCELONA, Spain, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to identify plasma-based biomarkers that could indicate a person’s likelihood of developing Parkinson’s disease (PD) many years before clinical diagnosis. The initiative, called “Chronos-PD,” could accelerate the discovery of new diagnostic tools as well as the identification and development of novel disease-modifying therapeutics.
PD affects nearly 1 million people in the U.S. and more than 6 million people worldwide.1 It occurs when brain cells that make dopamine, a chemical that coordinates movement, stop working or die. Despite decades of research and treatment advancement, the understanding of the drivers of the disease remains limited.
Today physicians use a combination of a person’s medical history, physical examination and brain imaging tests to diagnose PD. By the time the disorder is detected, it is often too late to slow its progression much less reverse the damage. This leaves early detection biomarkers as one of the most urgent needs for making further headway in therapeutic interventions to halt if not reverse the disease before it is too late.
The $21 million award will fund a pilot study to analyze longitudinal plasma samples covering a period of up to 10 years. This will enable researchers to track how distinct plasma proteins evolve over time in people with PD, which could help establish an early-warning system for the emergence of the disease.
Grifols’ repository of PD plasma samples is just a fraction of the more than 100 million samples the company has collected for nearly 15 years. Its proprietary bank is one of the world’s largest collections of biospecimens and contains plasma representing thousands of disease states connected to real-world health data. The same analyses applied to the PD samples can be replicated in other diseases and disease states across many therapeutic areas.
The unique plasma assets serve as the foundation of the Chronos-PD program, driving advanced research at Grifols subsidiary Alkahest, which is leading the initiative given its specialization in the use of AI and integrative analysis of multiomics and real-world data in diagnostic and therapeutic drug discovery.
“Our groundbreaking initiative leverages Grifols’ one-of-a-kind storehouse of well-preserved plasma samples, the most comprehensive technology platforms and our unique plasma proteomics expertise,” said Dr. Jörg Schüttrumpf, Grifols Chief Scientific Innovation Officer. “Going back in time to search for the earliest signs of PD, even before symptoms appear, has potential to revolutionize PD management. The hope is to accelerate and ultimately develop new diagnostics and disease-modifying therapeutics that could mitigate or even prevent the condition from manifesting itself. Our vision is that this platform continues to grow in terms of knowledge, partnerships and its ability to help society advance in fighting some of the world’s most pressing public health challenges.”
“At MJFF, our mission is to accelerate breakthroughs for people living with Parkinson’s by funding diverse and innovative approaches,” said Shalini Padmanabhan, senior vice president of translational research, MJFF. “Identifying reliable biomarkers for Parkinson’s disease is essential to unlocking earlier diagnosis and more effective treatments. Grifols’ research on a plasma-based biomarker to detect PD at its earliest stage — before progression begins — aims to helps us understand the biology of individuals who may be at risk and paves the way for transformative breakthroughs in care and prevention.”
About Grifols
Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces, and provides innovative healthcare services and solutions in more than 110 countries.
Patient needs and Grifols’ ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company’s innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology, and infectious diseases.
A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world’s largest with over 390 across North America, Europe, Africa and the Middle East, and China.
As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.
Grifols, with more than 23,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership.
The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE: GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE: GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ: GRFS).
For more information about Grifols, please visit grifols.com
________________________
MEDIA CONTACTS:
Grifols
media@grifols.com
Tel. +34 93 571 00 02
Investors
Investors Relations & Sustainability
inversores@grifols.com - investors@grifols.com
sostenibilidad@grifols.com - sustainability@grifols.com
Tel. +34 93 571 02 21
LEGAL DISCLAIMER
The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.
________________________
1 The Michael J. Fox Foundation for Parkinson’s Research
